PubMed

Molecular markers and death from prostate cancer.

Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK.

Ann Intern Med. 2009 May 5;150(9):595-603.PMID: 19414838 [PubMed - indexed for MEDLINE]Related articlesFree article

Molecular markers and mortality in prostate cancer.

Concato J, Jain D, Li WW, Risch HA, Uchio EM, Wells CK.

BJU Int. 2007 Dec;100(6):1259-63. Epub 2007 Sep 10.PMID: 17850375 [PubMed - indexed for MEDLINE]Related articles

Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.

Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C.

Lancet Oncol. 2008 Apr;9(4):342-51. Epub 2008 Mar 17.PMID: 18343725 [PubMed - indexed for MEDLINE]Related articles

Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.

Moul JW.

Eur Urol. 1999;35(5-6):399-407. Review.PMID: 10325496 [PubMed - indexed for MEDLINE]Related articles

Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.

Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML.

Cancer. 2002 Sep 1;95(5):1028-36.PMID: 12209687 [PubMed - indexed for MEDLINE]Related articlesFree article

p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.

Borre M, Stausbol-Gron B, Overgaard J.

J Urol. 2000 Sep;164(3 Pt 1):716-21.PMID: 10953132 [PubMed - indexed for MEDLINE]Related articles

Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer.

Chamie K, DeVere White RW, Lee D, Ok JH, Ellison LM.

Cancer. 2008 Nov 1;113(9):2464-70.PMID: 18666213 [PubMed - indexed for MEDLINE]Related articlesFree article

Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.

Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA.

Cancer. 2007 Sep 15;110(6):1248-54.PMID: 17674353 [PubMed - indexed for MEDLINE]Related articlesFree article

PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.

Patel AA, Chen MH, Renshaw AA, D'Amico AV.

JAMA. 2007 Oct 3;298(13):1533-8.PMID: 17911498 [PubMed - indexed for MEDLINE]Related articlesFree article

Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.

Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR.

Cancer. 2007 Mar 15;109(6):1192-202.PMID: 17311344 [PubMed - indexed for MEDLINE]Related articlesFree article

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.

D'Amico AV, Renshaw AA, Sussman B, Chen MH.

JAMA. 2005 Jul 27;294(4):440-7.PMID: 16046650 [PubMed - indexed for MEDLINE]Related articlesFree article

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis.

Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ.

Lancet Oncol. 2008 Nov;9(11):1039-47. Epub 2008 Oct 3.PMID: 18835745 [PubMed - indexed for MEDLINE]Related articlesFree article

CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.

Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW.

J Urol. 1998 Aug;160(2):459-65.PMID: 9679898 [PubMed - indexed for MEDLINE]Related articles

Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.

Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA.

J Natl Cancer Inst. 2003 May 7;95(9):661-8.PMID: 12734317 [PubMed - indexed for MEDLINE]Related articlesFree article

Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review.

Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, Hamdy F, Clarke N, Staffurth J.

Health Technol Assess. 2009 Jan;13(5):iii, xi-xiii 1-219. Review.PMID: 19128541 [PubMed - indexed for MEDLINE]Related articlesFree article

Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.

D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ.

J Urol. 2006 Dec;176(6 Pt 2):S11-5.PMID: 17084157 [PubMed - indexed for MEDLINE]Related articles

Sarcomatoid carcinoma of the prostate: a study of 42 cases.

Hansel DE, Epstein JI.

Am J Surg Pathol. 2006 Oct;30(10):1316-21.PMID: 17001164 [PubMed - indexed for MEDLINE]Related articles

Prognostic factors in prostate cancer.

Stattin P.

Scand J Urol Nephrol Suppl. 1997;185:1-46.PMID: 9249905 [PubMed - indexed for MEDLINE]Related articles

Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.

Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.

J Urol. 2005 Dec;174(6):2181-5.PMID: 16280760 [PubMed - indexed for MEDLINE]Related articles

Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer.

Beyer DC, Thomas T, Hilbe J, Swenson V.

Brachytherapy. 2003;2(2):77-84.PMID: 15062144 [PubMed - indexed for MEDLINE]Related articles